Moderna's Flu Vaccine Shows Promise, Paving Way for Combination Shot
Key Insights
Moderna's mRNA-based flu vaccine (mRNA-1010) produced a stronger immune response than existing flu shots in a late-stage trial.
The company plans to seek approval for its standalone flu vaccine and resubmit its application for a combination COVID-19 and flu shot.
A combination shot could improve vaccination rates, as nearly half of American adults get a flu shot annually, compared to only about 23% for the latest COVID vaccine.
The trial involved over 40,000 adults aged 50 and above across 11 countries, with Moderna's shot showing 27% higher efficacy than existing vaccines.
Why this matters: A more effective and convenient combination vaccine could significantly reduce flu-related hospitalizations and outpatient visits, which reached a 15-year high in the 2024-2025 season, with over 600,000 Americans hospitalized.
In-Depth Analysis
Moderna's mRNA technology allows for faster vaccine development compared to traditional methods. This agility could lead to better-matched vaccines each flu season. The recent positive trial results mark a turnaround for Moderna, which has faced challenges, including the decline of its COVID business and changes in vaccine policy.
The development of a combination vaccine aligns with public health goals to improve standalone flu shot effectiveness, particularly as the U.S. experienced one of its worst flu seasons in 15 years. With the new data, Moderna intends to resubmit the application for the combination vaccine and file for approval of its stand-alone flu shot later this year.
How to Prepare: Stay informed about vaccine availability and consult healthcare providers about the best options for protection against flu and COVID-19.
Who This Affects Most: Older adults (65+) and individuals with risk factors benefit significantly from more effective vaccines.
FAQs
Q: What is mRNA-1010?
mRNA-1010 is Moderna's experimental mRNA-based flu vaccine.
Q: How effective is Moderna's flu vaccine?
In a late-stage trial, it was 27% more effective than existing flu vaccines in adults 50 and older.
Q: What are the next steps for Moderna?
Moderna plans to seek approval for its standalone flu shot and resubmit its application for a combination COVID-19 and flu shot.
Key Takeaways
Moderna's flu vaccine shows promising results and is more effective than current options.
A combination COVID-19 and flu shot could simplify vaccination and increase uptake.
The development uses mRNA technology which could lead to better matched vaccines each flu season.
Stay informed and consult your healthcare provider about available vaccines.
Discussion
Do you think a combination COVID-19 and flu shot will increase vaccination rates? Let us know!
Share this article with others who need to stay ahead of this trend!
⚠ Disclaimer: Yanuki provides article summaries and links for reference only. Yanuki does not endorse, verify, or guarantee the accuracy of third-party sources. Please review original sources and verify information independently. Managed by the Yanuki Data Engine. Full Disclaimer